Clinical Trial Registration Sample Clauses

Clinical Trial Registration. In all cases, Merck shall have the right to register clinical trials and publish the results or summaries of results of any clinical trials conducted hereunder with respect to any Collaboration Compound or Collaboration Product on xxxxxxxxxxxxxx.xxx or other similar registry, in accordance with Applicable Law. 6.7
Sample 1
AutoNDA by SimpleDocs
Clinical Trial Registration. If MSD exercises the Option, MSD shall have the right and responsibility to register clinical trials and publish the results or summaries of results of any clinical trials conducted hereunder with respect to any Program Antigen or Product on xxxxxxxxxxxxxx.xxx or other similar registry.
Sample 1
Clinical Trial Registration. CHINA This is the process of assembling, summarizing and translating all pre-clinical and clinical information relating to prostaglandin E-1 from the literature as well as from NexMed's trials and submitting this package to the Ministry of Health. Upon review of this package, the Ministry will issue Clinical Trial Registration Approval allowing the trial to Commence or advise us as to the proper pathway. The assumption has been made that this clinical trial will be conducted under U.S. Good Clinical Practice conditions and the data from the trial will be able to be used worldwide to augment other submissions All work both in US and in China to prepare this package is covered by one charge as indicated in Exhibit B and listed as "Clinical Trial Registration Process". II. PREPARATION OF STUDY MATERIALS INNAPHARMA assumes that there will be further modifications to the protocol submitted to the Chinese regulatory authorities. Innapharma will work with the Chinese regulatory authorities to produce a final Protocol that satisfies all parties. Innapharma will develop and design the case report forms (annotated in Chinese). It has been assumed that the clinical supplies will be produced, packaged and shipped to investigative sites by NexMed. III. INITIATION OF STUDY Innapharma will work with the Ministry of Health to select the most qualified and experienced investigative sites for this study. Innapharma will negotiate all investigator grants and provide a duly constituted local IRB. Innapharma will conduct pre-study qualification visits to all sites. Upon satisfactory approval each site will be shipped a pre-study package of documents to prepare and submit to Innapharma as per GCP. INITIATION VISITS I SITE COORDINATOR TRAINING During the initiation visits study coordination training sessions to review protocol / CRFs will be developed and conducted by INNAPHARMA personnel at study initiation visits for all investigative sites involved in the clinical trial. IV. CONDUCT OF STUDY PATIENT GRANTS Innapharma will manage grant payments to all investigators. STUDY MONITORING INNAPHARMA will select study monitors from the Innapharma China Monitor Network. All monitors are medical doctors. Monitors will be chosen based on therapeutic experience as well as location. INNAPHARMA will utilize local monitors whenever possible to minimize travel time and costs. ONGOING REPORTS SERIOUS ADVERSE EVENTS Serious adverse event reports will be forwarded to the sponsor within 24 hours...
Sample 1
Clinical Trial Registration. CHINA This is the process of assembling, summarizing and translating all pre-clinical and clinical information relating to work that has been completed with the device to date by NexMed as well as any related devices on the market in the US or in China. The strategy will be to equate this herpes device with already marketed TENS devices which will make the clinical registration process much easier and quicker. Innapharma China will then submit this package to the Ministry of Public Health. Upon review of this package, the Ministry will issue Clinical Trial Registration Approval allowing the trial to begin or advise us as to the proper pathway. The assumption has been made that this clinical trial will be conducted under U.S. Good Clinical Practice conditions and the data from the trial will be submitable worldwide to augment other submissions
Sample 1
Clinical Trial Registration. MEMORY shall register each clinical trial to be conducted pursuant to the Development Program with (i) SMRI’s quarterly trial reporting system and (ii) if and to the extent required by law, the US FDA’s xxx.XxxxxxxxXxxxx.xxx website.
Sample 1
Clinical Trial Registration. Prior to the initiation of Study enrollment, Sponsor shall be responsible for posting the Study on a clinical trial registry which meets the criteria and contains the information required by the International Committee of Medical Journal Editors (“ICMJE”) for publication and meets the requirements of the Food and Drug Administration (“FDA”) and any other state or federal law pertaining to registration of the Study. Sponsor shall be responsible for updating such registration as required to comply with updates to any such ICMJE, FDA, and/or legal requirements.
Sample 1
Clinical Trial Registration. This clinical trial will be registered on the “xxxxxxxxxxxxxx.xxx” clinical trial registry website as required by 42 USC 282(j).
Sample 1
AutoNDA by SimpleDocs

Related to Clinical Trial Registration

  • Initial Registration The Company shall file a Registration Statement under the Securities Act promptly, but in any event within thirty (30) days following the Closing, to permit the public resale of all the Registrable Securities held by the Holders from time to time as permitted by Rule 415 under the Securities Act (or any successor or similar provision adopted by the Commission then in effect) (“Rule 415”) on the terms and conditions specified in this subsection 2.1.1 and shall use its commercially reasonable efforts to cause such Registration Statement to be declared effective as soon as practicable after the filing thereof, but in no event later than sixty (60) days following the filing deadline (the “Effectiveness Deadline”); provided, that the Effectiveness Deadline shall be extended to ninety (90) days after the filing deadline if the Registration Statement is reviewed by, and receives comments from, the Commission. The Registration Statement filed with the Commission pursuant to this subsection 2.1.1 shall be a shelf registration statement on Form S-1 (a “Form S-1”) or such other form of registration statement as is then available to effect a registration for resale of such Registrable Securities, covering such Registrable Securities, and shall contain a Prospectus in such form as to permit any Holder to sell such Registrable Securities pursuant to Rule 415 at any time beginning on the effective date for such Registration Statement. A Registration Statement filed pursuant to this subsection 2.1.1 shall provide for the resale pursuant to any method or combination of methods legally available to, and requested by, the Holders. The Company shall use its commercially reasonable efforts to cause a Registration Statement filed pursuant to this subsection 2.1.1 to remain effective, and to be supplemented and amended to the extent necessary to ensure that such Registration Statement is available or, if not available, that another Registration Statement is available, for the resale of all the Registrable Securities held by the Holders until all such Registrable Securities have ceased to be Registrable Securities. As soon as practicable following the effective date of a Registration Statement filed pursuant to this subsection 2.1.1, but in any event within two (2) business days of such date, the Company shall notify the Holders of the effectiveness of such Registration Statement. When effective, a Registration Statement filed pursuant to this subsection 2.1.1 (including the documents incorporated therein by reference) will comply as to form in all material respects with all applicable requirements of the Securities Act and the Exchange Act and will not contain a Misstatement.

  • Initial Registration Statement Promptly following the closing of the Merger Agreement and Plan of Reorganization dated as of January ____, 2007, among the Corporation, Elite FX, Inc., and other parties named therein (the "Closing Date") (but no later than one hundred and eight (180) days after the Closing Date), the Corporation shall use its reasonable best efforts to cause to be filed and declared effective as soon as reasonably practicable (but in no event later than 30 days after the SEC issues a no review letter) a registration statement under the Securities Act of 1933 and the rules promulgated thereunder (the "1933 Act"), covering the resale of the Registrable Securities held by the Subscribers, Nugent, Baudanza, Horn and Investa, if any, plus the number of shares of Common Stock necessary to permit the exercise in full of the Penalty Warrants outstanding or issuable on the date of filing. At the time the Registration Statement is declared effective, the Registration Statement shall include all shares of Common Stock exercisable under all Penalty Warrants outstanding or issuable at such time, if any. Such Registration Statement also shall cover, to the extent allowable under the 1933 Act (including Rule 416), such indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions with respect to the Registrable Securities. No securities held by a third party shall be included in such Registration Statement without the consent of the Subscribers. The Registration Statement (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided in accordance with Section 3(c) hereof to the Subscribers and their counsel prior to its filing or other submission. If a Registration Statement covering the Registrable Securities is not filed with the SEC within one hundred and eighty (180) days of the Closing Date (the "Registration Date"), except as excused pursuant to Section 2(d) below, for each 30-day period (or pro rata for any portion thereof) following the Registration Date during which no Registration Statement is filed with respect to the Registrable Securities, the Corporation will issue Penalty Warrants as set forth in Section 8 below in respect of any Registrable Shares still held by any Subscriber, Nugent, Baudanza, Horn or Investa, if any; provided, however, that no Penalty Warrants shall be issuable to any Subscriber, Nugent, Baudanza, Horn or to Investa in the event such party does not hold or no longer holds Registrable Securities at the time any Penalty Warrants are to be issued.

  • Maintaining a Registration Statement The Company shall maintain the effectiveness of any Registration Statement that has been declared effective at all times during the Commitment Period, provided, however, that if the Company has received notification pursuant to Section 2.04 that the Investor has completed resales pursuant to the Registration Statement for the full Commitment Amount, then the Company shall be under no further obligation to maintain the effectiveness of the Registration Statement. Notwithstanding anything to the contrary contained in this Agreement, the Company shall ensure that, when filed, each Registration Statement (including, without limitation, all amendments and supplements thereto) and the prospectus (including, without limitation, all amendments and supplements thereto) used in connection with such Registration Statement shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein (in the case of prospectuses, in the light of the circumstances in which they were made) not misleading. During the Commitment Period, the Company shall notify the Investor promptly if (i) the Registration Statement shall cease to be effective under the Securities Act, (ii) the Common Shares shall cease to be authorized for listing on the Principal Market, (iii) the Common Shares cease to be registered under Section 12(b) or Section 12(g) of the Exchange Act or (iv) the Company fails to file in a timely manner all reports and other documents required of it as a reporting company under the Exchange Act.

  • Additional Registration Statement To the extent that the Registration Statement is not available for the sales of the Shares as contemplated by this Agreement, the Company shall file a new registration statement with respect to any additional shares of Common Stock necessary to complete such sales of the Shares and shall cause such registration statement to become effective as promptly as practicable. After the effectiveness of any such registration statement, all references to “Registration Statement” included in this Agreement shall be deemed to include such new registration statement, including all documents incorporated by reference therein pursuant to Item 12 of Form S-3, and all references to “Base Prospectus” included in this Agreement shall be deemed to include the final form of prospectus, including all documents incorporated therein by reference, included in any such registration statement at the time such registration statement became effective.

  • Initial Registration Statement Effective The Initial Registration Statement covering the resale by the Investor of the Registrable Securities included therein filed by the Company with the Commission pursuant to Section 2(a) of the Registration Rights Agreement, and any post-effective amendment thereto required to be filed by the Company with the Commission after the Commencement Date and prior to the applicable Purchase Date pursuant to the Registration Rights Agreement, in each case shall have been declared effective under the Securities Act by the Commission and shall remain effective for the applicable Registration Period, and the Investor shall be permitted to utilize the Prospectus therein, and any Prospectus Supplement thereto, to resell (a) all of the Commitment Shares, (b) all of the Shares included in the Initial Registration Statement, and any post-effective amendment thereto, that have been issued and sold to the Investor hereunder pursuant to all VWAP Purchase Notices and Intraday VWAP Purchase Notices (as applicable) delivered by the Company to the Investor prior to such applicable Purchase Date and (c) all of the Shares included in the Initial Registration Statement, and any post-effective amendment thereto, that are issuable pursuant to the applicable VWAP Purchase Notice or Intraday VWAP Purchase Notice (as applicable) delivered by the Company to the Investor with respect to a VWAP Purchase or an Intraday VWAP Purchase (as applicable) to be effected hereunder on such applicable Purchase Date.

  • Additional Registration Statements Until the Applicable Date (as defined below) and at any time thereafter while any Registration Statement is not effective or the prospectus contained therein is not available for use or any Current Public Information Failure (as defined in the Registration Rights Agreement) exists, the Company shall not file a registration statement or an offering statement under the 1933 Act relating to securities that are not the Registrable Securities (other than a registration statement on Form S-8 or such supplements or amendments to registration statements that are outstanding and have been declared effective by the SEC as of the date hereof (solely to the extent necessary to keep such registration statements effective and available and not with respect to any Subsequent Placement)). “Applicable Date” means the earlier of (x) the first date on which the resale by the Buyers of all the Registrable Securities required to be filed on the initial Registration Statement (as defined in the Registration Rights Agreement) pursuant to the Registration Rights Agreement is declared effective by the SEC (and each prospectus contained therein is available for use on such date) or (y) the first date on which all of the Registrable Securities are eligible to be resold by the Buyers pursuant to Rule 144 (or, if a Current Public Information Failure has occurred and is continuing, such later date after which the Company has cured such Current Public Information Failure).

  • SEC Registration The Parties mutually agree to use commercially reasonable efforts to maintain effective registration statements with the Securities and Exchange Commission with respect to the long-term incentive awards to the extent any such registration statement is required by applicable Law.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!